Aligos Therapeutics, Inc. · NASDAQ:ALGS
Aligos Therapeutics — Investor Presentation (November 2020)
35 slides from Aligos Therapeutics's investor presentation, November 2020
Slide 1: Corporate Presentation
Lawrence M. Blatt, Ph.D. CEO & Co-Founder Corporate Presentation 1
Slide 2: Disclosures
Disclosures This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective drugs and drug candidates
Slide 3: Aligos Therapeutics Highlights
Aligos Therapeutics Highlights Our Mission Our Platforms Our Strategy Our Team Develop novel therapeutics to Proprietary oligonucleotide Develop pharmacologically Decades of drug discovery address unmet medical needs and small molecule platforms optimized drug candidates and development experience i
Slide 4: Our Platforms, Capabilities and Collaborations
Our Platforms, Capabilities and Collaborations Oligonucleotide Modalities Rega / CD3 Small Molecule Chemistry Collaboration COVID Protease AM Chemicals Chemistry, Manufacturing Proprietary GalNAc and Controls Agency for Innovation and Entrepreneurship (VLAIO) Biological Sciences Luxna Biotech 3rd Ge
Slide 5: A Lesson from Chronic Hepatitis C
A Lesson from Chronic Hepatitis C From First Movers to Best-in-Class Regimens • Efficacy Safety Convenience • Standard of care treatment until 2011 – Pegylated interferon + ribavirin – 48-weeks, ~50% cure rate, poorly tolerated • Protease inhibitors – First clinical entrant – BILN-2061 (2001) –
Slide 6: Our Pipeline of Wholly Owned Assets
Our Pipeline of Wholly Owned Assets Anticipated Candidate Indication MOA Discovery Nonclinical Phase 1 Phase 2 Phase 3 Milestones Initial ALG-010133 CHB STOPS Phase 1 Data Initial ALG-000184 CHB CAM Phase 1 Data Phase 1 ALG-020572 CHB ASO Start Phase 1 ALG-125097 CHB siRNA Start Phase 1 ALG-055009 N
Slide 7: Chronic Hepatitis B
ALIGOS THERAPEUTICS Chronic Hepatitis B
Slide 8: CHB Epidemiology & Our Portfolio
CHB Epidemiology & Our Portfolio • CHB Epidemiology* - Most common chronic viral infection in world – >290 million carriers worldwide (2020) – ~8 million in US, EU, Japan (2015) – Responsible for ~900,000 deaths/year (2015) • Our Portfolio – Potentially best-in-class drug candidates against validate
Slide 9: STOPS
STOPS ALG-010133, a novel, chemically optimized poly-AC oligonucleotide analog 9
Slide 10: Poly AC Oligonucleotides Have Clinical Validation
Poly AC Oligonucleotides Have Clinical Validation • Replicor 102 Study* HBsAg Reduction in REP 401 Study – REP 2139-Ca Monotherapy – 500 mg Q-weekly, 2-hr IV administration – Significant reduction in HBsAg observed • Replicor 401 Study (Figure**) – REP 2139-Mg or REP 2165-Mg – 250 mg Q-weekly, 2-hr
Slide 11: ALG-010133 Our Lead STOPS Molecule
ALG-010133 Our Lead STOPS Molecule Significantly greater potency vs. reference Poly-AC oligonucleotide* EC50 = 3.2 nM EC50 = 3.86 nM EC50 = 339.5 nM EC50 = 343.3 nM Similar potency improvement also seen in primary human hepatic cells *ALG-010004 has an identical oligonucleotide sequence as REP 2139.
Slide 12: CAM
CAM ALG-000184, a prodrug of ALG-001075 12
Slide 13: CAMs Have Demonstrated Clinical Anti-HBV Activity
CAMs Have Demonstrated Clinical Anti-HBV Activity Assembly ABI-H0731 at 300 mg QD in HBeAg (+) treatment naïve CHB patients in combination with the nucleoside analog entecavir Unlike nucleoside analogues when used in monotherapy, reductions in HBV pgRNA were also observed ABI-H0731 = Vebicorvir. Mod
Slide 14: Our CAM Demonstrates Superior In Vitro Potency vs. Other CAMs
Our CAM Demonstrates Superior In Vitro Potency vs. Other Known CAMs in Clinical Development Phase 1 14
Slide 15: ALG-001075 Potent In Vivo Activity in the AAV-HBV Mouse Model
ALG-001075 Potent In Vivo Activity in the AAV-HBV Mouse Model Serum HBV DNA Dose dependent reductions in HBV DNA observed across treatment groups >5 log10 IU/mL reduction in HBV DNA relative to placebo in the 15 mg/kg BID treatment group HBV DNA levels in AAV-HBV infected mice when dosed orally for
Slide 16: Oligonucleotide Approaches
Oligonucleotide Approaches ASO (ALG-020572) siRNA (ALG-125097) 16
Slide 17: ASOs Have Demonstrated Clinical Anti-HBV Activity
ASOs Have Demonstrated Clinical Anti-HBV Activity in HBsAg (log10 IU/mL) Change from Baseline HBsAg reductions at Day 29 among nucleos(t)ide analog (NA) naïve and treated CHB patients receiving six doses of 300 mg GSK-3228836 or placebo over 22 days Modified from Yuen et al., EASL dILC2020. #AS067.
Slide 18: ALG-020572 Discovery of our ASO Drug Candidate
ALG-020572 Discovery of our ASO Drug Candidate • We have utilized our bioinformatics approach in the selection and optimization of novel ASO constructs • We optimized our sequences using our proprietary Luxna Biotech chemistries to potentially enhance in vitro potency, stability and safety – Luxna x
Slide 19: ALG-020572 Our ASO Drug Candidate in the Mouse AAV-HBV Model
ALG-020572 Our ASO Drug Candidate in the Mouse AAV-HBV Model Potent in vivo activity of ALG-020572 in the AAV-HBV mouse model without ALT elevation 19
Slide 20: siRNAs Have Demonstrated Clinical Anti-HBV Activity
siRNAs Have Demonstrated Clinical Anti-HBV Activity JNJ-3989, a GalNAc conjugated, dual (X + S) trigger siRNA JNJ-3989 in combination with a nucleos(t)ide analog demonstrated durable HBsAg reductions following three monthly doses Modified from Gane E, et al. EASL dILC2020. #AS068. 20
Slide 21: ALG-125097 Discovery of our siRNA Drug Candidate
ALG-125097 Discovery of our siRNA Drug Candidate • We have utilized our bioinformatics approach in the selection and optimization of novel siRNA target sequences • We optimized siRNA sequences using our proprietary technology including chemical modifications and liver targeting conjugation to maximi
Slide 22: ALG-125097 siRNA Drug Candidate in the Mouse AAV-HBV Model
ALG-125097 siRNA Drug Candidate in the Mouse AAV-HBV Model Potent and sustained antiviral activity following a single dose through 28-days of monitoring 22
Slide 23: Chronic Hepatitis B Clinical Development Combination Strategy
Chronic Hepatitis B Clinical Development Combination Strategy 23
Slide 24: Our CHB Clinical Development Strategy
Our CHB Clinical Development Strategy DNA = deoxyribonucleic acid; HV = healthy volunteer; PK = pharmacokinetics; PD = pharmacodynamics; SAD/MAD = single/multiple ascending dose; SOC = standard of care. 24
Slide 25: Aligos CHB Clinical Development Timelines
Aligos CHB Clinical Development Timelines Phase 1 Target Timelines* ALG-010133 (STOPS) SAD/MAD in HV Multiple dosing CHB ALG-000184 (CAM) SAD/MAD in HV Multiple dosing CHB ALG-025072 Multiple (ASO) SAD/MAD in HV Dosing CHB SAD/ ALG-125097 MAD (siRNA) in HV Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun
Slide 26: NASH
ALIGOS THERAPEUTICS NASH ALG-055009 26
Slide 27: THR-β Agonists are Clinically Validated
THR-β Agonists are Clinically Validated THR-β agonists have demonstrated beneficial effects on serum lipid levels and liver histology ^All dose levels pooled. *Placebo corrected values. ** In patients with NASH, Harrison, Lancet, 2019. Resmetirom = MGL-3196. *** In patient with NAFLD, hyperlipidemia
Slide 28: ALG-055009 More Potent and Selective In Vitro than MGL-3196 and VK-2809
ALG-055009 More Potent and Selective In Vitro than MGL-3196 and VK-2809 Relative THR-α and THR-β Activity in Cell-Based Assays In vitro, ALG-055009 is 5-47x more potent compared to resmetirom (MGL-3196) and 2-3x more selective for THR-β than VK-2809* High β selectivity and potency may improve risk-b
Slide 29: ALG-055009 Dose-Related Effect on Serum Lipids in the DIO Mouse Model
ALG-055009 Dose-Related Effect on Serum Lipids in the DIO Mouse Model 34% 59% 0.25 mg/kg ALG-055009 resulted in greater serum lipid reductions in the DIO model compared to what has been previously reported for VK-2809 and resmetirom at exposures equivalent to Phase 2b/3 clinical doses without a thyr
Slide 30: Our NASH Strategy
Our NASH Strategy • Advance our lead THR-β drug, ALG-055009 – Phase 1 proof of concept study planned for 2021-2022 › Provide clinical confirmation of the safety, PK and efficacy advantages identified in nonclinical studies › Data readouts expected to begin in 2022 • Madrigal Phase 3 and VK-2809 Phas
Slide 31: Coronavirus
ALIGOS THERAPEUTICS Coronavirus 31
Slide 32: Our Approach to Developing a Broad Coronavirus Treatment
Our Approach to Developing a Broad Coronavirus Treatment • We are leveraging our virology and chemistry expertise to develop purpose-built drugs with distinct MOAs – Coronavirus protease inhibitors in collaboration with CD3/Rega at KU Leuven – Oligonucleotides • We are aiming to develop drug candida
Slide 33: Coronavirus Protease Inhibitor Collaboration CD3/Rega at KU Leuven
Coronavirus Protease Inhibitor Collaboration CD3/Rega at KU Leuven Centre for Drug Design Rega Institute and Discovery (“CD3”) Professor Johan Neyts KU Leuven Identified multiple nM potent coronavirus protease inhibitors 33
Slide 34: Aligos Therapeutics Summary
Aligos Therapeutics Summary • We have assembled a world-class team with a proven track record of success • Strong management team supported by top tier investors – $100M* Series A in September 2018, $125M** Series B in December 2019 / October 2020 – $167.2M gross proceeds from our IPO in October 202
Slide 35: Aligos Therapeutics
ALIGOS THERAPEUTICS
Aligos Therapeutics — Investor Presentation (November 2020) on 6ix